Gilead Sciences Inc (NAS:GILD)
$ 67.9 0.18 (0.27%) Market Cap: 84.59 Bil Enterprise Value: 104.85 Bil PE Ratio: 188.61 PB Ratio: 4.83 GF Score: 74/100

Gilead Sciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 04:30PM GMT
Release Date Price: $71.76 (+1.86%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Well, great. Good afternoon, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley.

Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So pleased to have Gilead with us next, and Dan O'Day, the CEO.

Questions & Answers

Matthew Kelsey Harrison;Daniel P. O;Day
Morgan Stanley, Research Division - Executive Director

Dan, I thought maybe a good place to start is just a couple macro items that come up a lot and maybe aren't even Gilead specific, but sort of industry specific. There remains a lot of uncertainty about what's happening in D.C. And I think none of us really know what's happening with reconciliation or otherwise.

'

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot